http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
World Health Organization to Review Merck’s Investigational Ebola Vaccine for Emergency Use Assessment and Listing
-
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
-
Merck (MRK) Announces Expanded Indication for KEYTRUDA
-
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
-
Merck's (MRK) Elbasvir/Grazoprevir MAA Will New Come Under EMA CHMP Standard Review
-
Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir
-
Merck (MRK) Says GARDASIL 9 Age Expanded in Males 16-26
-
FDA Approves Expanded Age Indication for GARDASIL® 9 in Males
-
Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG and Merck's Checkpoint Inhibitor Keytruda in Patients with Non-Small Cell Lung Cancer
-
Eli Lilly & Co. (LLY), Merck (MRK) Enter Collaboration for Abemaciclib Phase 1
-
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA® Combination Trial
-
Merck (MRK) Presents KEYTRUDA Data at ASH 2015
-
Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA® (pembrolizumab) Data
-
Merck (MRK) Announces Receipt of RENFLEXIS Approval in Korea
-
Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS™ (Infliximab), a Biosimilar of Remicade, in Korea
-
Responses Observed in Three-Quarters of Heavily Pre-Treated Multiple Myeloma Patients Receiving KEYTRUDA® (pembrolizumab) Combined With Lenalidomide and Dexamethasone
-
Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma
-
New Survey Showed That Most People Living With HIV Were More Concerned About Their Other Chronic Health Conditions Than Their HIV
-
Merck Announces Increased Quarterly Dividend
-
Merck Announces Initial Results for KEYTRUDA® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Con
-
Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
-
New Studies Investigating the Use of KEYTRUDA® (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses
-
Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting®
-
Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Ther
-
Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infectio
-
Merck Provides Update on REVEAL Outcomes Study
-
Merck Animal Health to Acquire Harrisvaccines
-
Merck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation
-
Merck Statement on FDA Advisory Committee Meeting for BRIDION® (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium
-
Data on Vericiguat, Investigational Heart Failure Medicine, to be Presented as Late-Breaking Clinical Trial at the 2015 American Heart Association (AHA) Scientific Sessions
-
Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
-
GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
-
Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Advanced Colorectal Cancer
-
KEYTRUDA® (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award
-
Market Wrap: Suprise Dip in Confidence for Oct.; Apple Gains on iPhone Sales; Walgreens Boots Moves to Acquire Peer
-
Wall St. slips on rate uncertainty; Apple up after the bell
-
Merck Announces Third-Quarter 2015 Financial Results
-
Trading Radar for 10/26: Apple (AAPL), Twitter (TWTR), Alibaba (BABA), Comcast (CMCSA), Pfizer (PFE) Report
-
Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
-
Merck and the National Sleep Foundation Urge Insomnia Sufferers to Prioritize Sleep and Move Beyond Tired
-
Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations
-
Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal
-
Market’s Only Cancer Immunotherapy ETF Launches
-
Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma
-
Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal
-
KEYTRUDA® (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
-
Results from Merck’s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
-
Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment
-
FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Che
-
Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer

